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Abstract  1 
Introduction: Genome editing by programmable nucleases represents a promising tool that could be exploited 2 
to develop new therapeutic strategies to fight infectious diseases. These nucleases, such as zinc-finger 3 
nucleases, transcription activator-like effector nucleases, clustered regularly interspaced short palindromic 4 
repeat (CRISPR)-CRISPR-associated protein 9 (Cas9) and homing endonucleases, are molecular scissors that 5 
can be targeted at predetermined loci in order to modify the genome sequence of an organism.  6 
Areas covered: By perturbing genomic DNA at predetermined loci, programmable nucleases can be used as 7 
antiviral and antimicrobial treatment. This approach includes targeting of essential viral genes or viral 8 
sequences able, once mutated, to inhibit viral replication; repurposing of CRISPR-Cas9 system for lethal self-9 
targeting of bacteria; targeting antibiotic-resistance and virulence genes in bacteria, fungi, and parasites; 10 
engineering arthropod vectors to prevent vector-borne infections. 11 
Expert commentary: While progress has been done in demonstrating the feasibility of using genome editing 12 
as antimicrobial strategy, there are still many hurdles to overcome, such as the risk of off-target mutations, the 13 
raising of escape mutants, and the inefficiency of delivery methods, before translating results from preclinical 14 
studies into clinical applications.  15 
 16 
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1. Introduction 1 
Advancements in basic research have allowed dissecting pathogen structure, replication mechanisms, and 2 
virulence factors at molecular level, leading to the discovery of several new antimicrobial agents. However, 3 
notwithstanding these advances, infectious diseases still represent the third cause of mortality worldwide and 4 
the increasing emergence of multi-drug resistant pathogens is a matter of concern. Next generation 5 
technologies are now helping moving forward scientific knowledge and its translational applications at an 6 
unprecedented speed. Among these technologies, genome editing by programmable nucleases represents a 7 
promising tool that could be exploited to develop new therapeutic strategies to fight infectious diseases. These 8 
nucleases, such as zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), 9 
clustered regularly interspaced short palindromic repeat (CRISPR)-CRISPR-associated protein 9 (Cas9) and 10 
homing endonucleases (HEs), are molecular scissors that can be targeted at predetermined loci in order to 11 
modify the genome sequence of an organism. In this review, we will discuss the main applications of these 12 
gene editing tools with particular focus on their use as antiviral and antimicrobial agents and on the critical 13 
issues that need to be faced in order to translate promising results from basic research into new treatment 14 
modalities for evaluation in clinical trials. 15 
 16 
2. Genome editing tools 17 
Despite their architectural and origin differences, all four classes of engineered nucleases mostly used so far, 18 
ZNFs, TALENs, CRISPR-Cas, and HEs have one common final aim: to exert DNA double strand brakes 19 
(DSBs) into preselected loci of a genome. The first three are composed of two basic units: one is responsible 20 
for DNA sequence recognition and bond and the other one, represented by the molecular scissors, for the DNA 21 
DSB. Once a DNA DSB occurs, the physiological cell machinery works in order to repair this rupture 22 
throughout two types of mechanisms: non-homologous end joining pathways (NHEJ) or homologous 23 
recombination (HR) [1]. NHEJ is an error prone mechanism that can introduce insertions or deletions (the so 24 
called indels) in the process of reuniting the DNA ends. These indels may be advantageous when they cause 25 
frameshifts resulting in gene knock-out due to mRNA degradation or production of non-functional proteins 26 
[2]. When a high copy number of an homologous sequence is introduced exogenously into a cells in the form 27 
of plasmids or single stranded oligonucleotides, HR can instead take place, allowing the new sequence to be 28 
introduced into the cell genome [3,4]. ZNFs are the first class of chimeric programmable nucleases that was 29 
applied for genome editing. Their first use dates back to 2001, when ZNFs were shown to promote HR at 30 
specific genomic sequences in Xenopus embryos [5]. Few years later, ZFNs were shown to allow the genetic 31 
correction of the SCID mutation in human cells by HR at high efficiency [6] and brought to the production of 32 
the first knockout rats via embryo microinjections [7]. Then, TALENs were applied as genome editing tools 33 
in human cells [8]. In 2013, two independent groups demonstrated that bacterial CRISPR-Cas9 system could 34 
be adapted to become programmable nuclease for genome editing very efficiently [9,10]. The DNA binding 35 
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domain of ZFNs is composed by a tandem array of C2H2 zinc fingers with each one recognizing a 3‑bp DNA 1 
sequence [11] and usually 3–6 zinc-fingers are used to generate a single ZFN subunit that binds to DNA 2 
sequences of 9–18 bp. The element responsible for DSBs of ZFNs is represented by the cleavage domain of 3 
bacterial restriction enzyme FokI that must dimerize in order to cleave DNA [12]. Consequently, binding of 4 
two ZFN monomers to two specific sites is required for effective double-strand DNA cleavage [13]. TALENs 5 
are similar to ZFNs as they rely on the same cleavage unit, the restriction enzyme FokI, and are so fore required 6 
to bind the DNA grove as dimers [8]. The DNA binding domain of TALENs is composed by TALE proteins, 7 
derived from the plant pathogenic Xanthomonas spp. bacteria [14], that comprise tandem arrays of 33–35 8 
amino acid repeats, each recognizing a single base-pair of the major groove [15]. Two amino acids at positions 9 
12 and 13 of each repeat domain [16], called repeat variable diresidues (RVDs), are responsible for the 10 
nucleotide specificity and four different RVDs are most widely used to recognize the four bases of the DNA. 11 
While both ZFNs and TALENs rely on a protein/DNA based interaction, CRISPR-Cas9 system is based on 12 
RNA/DNA interaction. In bacteria and archaea, the CRISPR-Cas system naturally provides adaptive immunity 13 
against invading phages or plasmids [17]. Briefly, CRISPR regions are incorporated into the bacterial genome, 14 
upon capture of a ~20 bp DNA fragments (called protospacer), from the foreign DNA of invading phages or 15 
plasmids. In type II CRISPR systems, the CRISPR regions together with an invariable target-independent 16 
trans-activating crRNA (tracrRNA) region are transcribed as pre-CRISPR RNA (pre-crRNA) and processed 17 
to give rise to target-specific crRNA [18]. Both crRNA and tracrRNA are complexed with the Cas9 protein to 18 
form an active DNA endonuclease, able to cleave a target DNA sequence composed of the 20‑bp guide 19 
sequence, represented by the protospacer and the 5ʹ‑NGG‑3ʹ sequence known as PAM (protospacer adjacent 20 
motif) [19]. Unlike the other classes of nucleases, in HEs the same domain mediates both DNA recognition 21 
and cleavage functions. In microbial organisms, phages, and viruses, HEs are small proteins naturally encoded 22 
by elements found within introns of the genome. HEs function by introducing DSBs within homologous alleles 23 
that lack the corresponding intron, which are subsequently repaired via HR using the allele containing the HN 24 
gene. HEs have been adapted for gene editing purposes by engineering the protein structure to facilitate DNA 25 
binding without modifying the cleavage activity [20].  26 
 27 
 28 
3. Viral infections 29 
When considering genome editing as strategies for antiviral therapy, error-prone NHEJ is the main mechanism 30 
by which programmable nucleases operate, by leading to the formation of indels able to perturb the DNA 31 
sequence of a virus present in infected cells or by targeting cellular key factors that are essential for virus entry, 32 
replication, or reactivation from latency. Since the target of programmable nucleases is a DNA sequence, this 33 
constrains the possibility to use these tools only against viruses that have a DNA-based genome or that passes 34 
through a viral-DNA intermediate easily accessible by the programmable nucleases, such as in the case of 35 
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human immunodeficiency virus (HIV). The CRISPR-Cas9 system has been recently modified to generate 1 
gRNAs that were complementary to the genome of hepatitis C virus (HCV), thus demonstrating the feasibility 2 
of targeting viruses with a RNA genome [21]. Finally, antiviral strategies that employ programmable nucleases 3 
seem to be more suited for chronic or persistent infections, characterized by the persistence of the viral genome 4 
as an episome in the nucleus or integrated into host chromosomes, than for acute infections, for which most of 5 
antiviral interventions are inefficacious after the onset of symptoms. Genome editing-based antiviral strategies 6 
are illustrated in Figure 1.  7 
3.1. Targeting the viral genome 8 
HIV has been a focus for the application of genome editing as antiviral therapy. HIV is a lentivirus that 9 
randomly integrates into the host cell genome and persists in CD4+ T cells. The integrated proviral genome 10 
serves both as template for gene transcription in the infected cells and for the latency of the virus [22]. By 11 
eliminating the integrated provirus, HIV infection could be eradicated. One of the first attempts to disrupt an 12 
integrated lentiviral provirus exploited HEs targeting a green-fluorescent protein (GFP) open reading frame, 13 
in which the wild-type recognition site for the HE, Y2 I-AniI, was inserted resulting in loss of GFP signal [23]. 14 
The two long terminal repeats (LTR) of HIV-1 and in particular the extremely conserved U3 and the 15 
transactivation response element (TAR) regions, which are critical for viral replication, have been targeted 16 
with engineered ZFNs [24] and TALENs [25], respectively. The ZFNs-U3 system could target and excise the 17 
full-length HIV-1 proviral DNA in infected human cell lines with an efficiency of about 30% without affecting 18 
cell cycle progression and cell proliferation [24], while TALENs demonstrated an editing efficiency of 55–19 
60% and could eliminate the production of viral particles in HIV-infected in cells [25]. Ebina et al. were the 20 
first to demonstrate the potential of the CRISPR-Cas9 system to edit the HIV-1 genome by blocking its 21 
expression via targeting the LTR promoter region and by showing disruption and excision of the latent provirus 22 
from human cells [26]. Then, several other studies showed that CRISPR-Cas9 targeting viral LTR or essential 23 
viral genes in the integrated provirus or in its pre-integration form (when the cDNA of the virus is free and 24 
readily targetable by nucleases) resulted in profound suppression of HIV-1 production and infection in CD4+ 25 
T cells [27-32]. Recently, Kaminski et al. [33], in their proof of concept work, demonstrated the feasibility of 26 
HIV genome editing in vivo by using a recombinant adeno-associated virus 9 (rAAV9) vector injected through 27 
the tail-vein in transgenic mice to deliver the gRNAs/Cas9. Treatment led to the excision of a 978 bp DNA 28 
fragment spanning between the LTR and Gag gene of integrated HIV-1 DNA in multiple organs such the 29 
spleen, liver, heart, lung and kidney as well as in the circulating lymphocytes [33]. In other studies, ZFNs were 30 
able to act as repressors of HIV [34,35] and to interfere with integration 36,37]. 31 
An alternative genome editing strategy to interfere with HIV infection is the so-called “shock and kill” 32 
approach, based on the reactivation of latent virus in infected cells, which, so far, has been attempted with 33 
chemical agents, such as a histone deacetylase inhibitors [38]. A particular, a mutant form of Cas9 that has lost 34 
its DNA cleavage activity, named CRISPR activation (CRISPRa), can be directed to induce HIV reactivation 35 
in latently infected cells, resulting in their recognition by host immune surveillance mechanisms [39]. 36 
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CRISPRa has been also fused to transcriptional activator domains directed to LTR sequences to drive virus 1 
replication and to induce HIV-1 reactivation [40-43].  2 
Hepatitis B virus (HBV) is a hepadnavirus whose genome is composed by a partially double-stranded circular 3 
DNA that, upon infection of hepatocytes, is transported to the nucleus and converted to a covalently closed, 4 
circular, double-stranded DNA (cccDNA), which remains episomal. The cccDNA is the template for 5 
transcription of the three main subgenomic RNAs and of the pregenomic RNA that is reverse transcribed into 6 
the negative-strand DNA, converted into partially dsDNAs, and used in part for the packaging of new viral 7 
particles and in part shipped to the nucleus where it becomes cccDNA [44]. The first examples of gene editing 8 
strategies applied as antiviral therapy for HBV infection include the use of ZNFs designed to bind HBV viral 9 
sequences to inactivate the episomal viral genome [45] and the use of self-complementary AAV (sc-AAV) 10 
vectors to deliver HBV-specific ZFNs to infected hepatocytes, resulting in decreased HBV DNA synthesis to 11 
near-baseline levels without significant toxicity [46]. The efficacy of anti-HBV TALENs was demonstrated 12 
by Bloom et al., who designed anti-HBV TALENs to target three HBV open reading frames (S, P and C) [47]. 13 
The S and C TALENs were able to cause intended mutations in the viral cccDNA, with an editing rate of 35% 14 
and 12%, respectively [47]. Hydrodynamic injection (HDI) of plasmids encoding HBV-targeted TALENs was 15 
used for in vivo delivery, which led to reduction of HBsAg levels by 90% and circulating viral particle 16 
equivalents by 70%, without relevant toxicity in treated mice [47]. The HBV model of HDI was also employed 17 
to suppress HBsAg expression by CRISPR-Cas9 system [48] and efficient targeting of the cccDNA and 18 
inhibition of HBV replication was also demonstrated in in vitro [49, 50] and in vivo models [51]. These in vivo 19 
experiments were performed in HBV-transgenic mice and other limited models of HBV infection, rather than 20 
in HBV infection in humanized mice or other physiologically relevant models, so further studies are needed 21 
before generalization of these results to human infection.  22 
Human papillomavirus (HPV), a DNA virus belonging to the Papillomaviridae family, is the leading cause of 23 
infection-related cancer in humans.  The virus infects the cells in the basal epithelial layer of the skin and 24 
mucosa, where its genome persists in the nucleus as an episome, without active replication. When these basal 25 
cells undergo differentiation into keratinocytes, migrating towards the surface of the epidermis, virus 26 
replication cycle is triggered, leading to the release of infectious viral particles [52]. The genome of oncogenic 27 
HPV types may integrate into cellular chromosomes and this causes overexpression of viral E6 and E7 28 
oncoproteins, which are responsible for cell transformation, mainly through inactivation of p53 and Rb, 29 
respectively [53]. Persistent overexpression of HPV E6/E7 is necessary for cell transformation and E6/E7 30 
inactivation leads to tumor regression [53]. The key role of E6 and E7 in HPV-driven tumors supports the use 31 
of genome editing tools targeting E6/E7 as anticancer therapy. Studies demonstrated that ZFNs, TALENs, and 32 
CRISPR-Cas9 directed against E6 and E7 efficiently cleaved both episomal and in integrated forms of the 33 
HPV genome, resulting in the disruption of target oncogenes [54-60]. In particular, ZFNs directed against E7 34 
of oncogenic HPV16 and HPV18 specifically inhibited growth, induced apoptosis and repressed xenograft 35 
formation in vivo of corresponding HPV16- and HPV18-positive cervical cancer cell lines [54]. Targeting 36 
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E6/E7 with TALENs induced apoptosis, inhibited growth, reduced tumorigenicity in nude mice and restored 1 
p53 and Rb in HPV-positive cell lines [60]. In a HPV16 transgenic mouse model of HPV-driven cancer, direct 2 
cervical application of polymer-complexed plasmids carrying HPV16-E7–targeted TALENs effectively 3 
mutated the E7 oncogene, reduced viral DNA load, and reversed the malignant phenotype [60]. Efficient 4 
cleavage of the HPV genome with the introduction inactivating mutations of the E6 and E7 genes was also 5 
achieved by using CRISPR-Cas9  with sgRNAs specific for HPV18 E6 or E7 [57]. Treatment resulted in the 6 
induction of p53 or Rb, respectively, cell cycle arrest and cell death [57]. These studies paved the way to the 7 
initiation of phase I clinical trials with the main objective to evaluate the safety of ZFNs (NCT02800369), 8 
TALENs, and CRISPR-Cas9 (NCT03057912) systems. In the NCT02800369 study, patients were treated with 9 
suppositories containing 500 µg of ZFN-603 or ZFN-758, which target the HPV16 E7 or HPV18 E7 oncogene, 10 
respectively. The primary outcome was the evaluation of safety by reporting treatment-related adverse events 11 
of ZFN-603 and ZFN-758 in HPV16-positive and HPV18-positive subjects, respectively. The secondary 12 
outcome was the evaluation of efficacy in a time frame of 6 months, by detection of HPV16 and HPV18 13 
persistence, changes in the number of dysplastic cells as measured by Pap test, and the number of patients 14 
without disease progression [61]. The primary objective of the NCT03057912 study was to evaluate the safety 15 
of therapeutic doses and the dosing regimen of TALENs and CRISPR/Cas9 plasmids targeting E6/E7 of 16 
HPV16 or HPV18. Both TALENs and CRISPR-Cas9 were formulated as plasmids in gel. The secondary 17 
objective of this study was to evaluate efficacy by measurement of HPV DNA load and cytological and 18 
histological regression at 3 and 6 months [62]. No results from these studies have been published so far. 19 
Several studies on other clinically relevant DNA viruses demonstrated the feasibility of viral genome targeting 20 
by programmable nucleases. Among these, Epstein-Barr virus (EBV) episomes have been disrupted by specific 21 
Cas9/sgRNAs combinations in a latent EBV infection model [63]; a three gRNAs- CRISPR-Cas9 system could 22 
suppress JCV T-antigen expression and inhibit viral replication in JCV transformed and in permissive cell 23 
lines [64]; delivery of HEs or CRISPR-Cas9 system targeting essential herpes simplex virus type 1 (HSV-1) 24 
genes could disrupt latent HSV genome or inhibit viral lytic replication in vitro [65-67].  25 
3.2. Targeting host factors required for viral infection and replication 26 
Host factors required for virus entry, replication, and pathogenesis are potential targets for genome editing 27 
interventions. This is the case for HIV-1 entry, which is mediated through interaction of gp120 and host CD4 28 
with the help of a coreceptor that, for nearly almost all primary isolates of HIV-1, is represented by chemokine 29 
receptor 5 (CCR5) [68]. The idea that this coreceptor could be used as a target for HIV-1-entry inhibition 30 
comes from the observation that individuals who carry a deletion of 32bp in the CCR5 gene, known as CCR5-31 
Δ32, are protected against R5 strains of HIV-1 [69]. Several preclinical studies showed that ZFNs directed to 32 
CCR5 were able to disrupt the gene in human CD4+ T cells and in CD34+ hematopoietic stem cells (HSCs), 33 
able to give rise to multi-lineage progeny with stably disrupted CCR5. The efficiency of gene disruption ranged 34 
from 17% to 25% when engrafted in immune-deficient or humanized mice, thus reducing HIV-1 levels and 35 
conferring resistance to HIV-1 infection [70-74]. Moving from bench to bedside, so far a few clinical trials 36 
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involving ZFN-mediated CCR5 disruption have been completed, with promising results. In these trials, CD4+ 1 
T cells or HSCs from HIV-1 infected patients were treated ex-vivo and then the corrected cells were reinfused 2 
into patients (NCT00842634, NCT01044654, NCT01252641 and NCT02500849). Safety of this protocol was 3 
evaluated in an open-label, nonrandomized, uncontrolled study of a single dose of ZFN-modified autologous 4 
CD4 T cells, in which the CCR5 gene was inactivated (NCT00842634) [75]. The study enrolled 12 HIV-5 
positive aviremic patients who were receiving highly active antiretroviral therapy. In six patients, antiretroviral 6 
treatment was interrupted 4 weeks after infusion of CD4 T cells, 11%- 28% of which were genetically 7 
modified. Treatment was well tolerated and only one serious adverse event occurred, attributed to a transfusion 8 
reaction. The count CD4 T-cells significantly increased after transfusion and, in patients who interrupted 9 
antiretroviral therapy, the decline in circulating CCR5-modified cells was significantly lower than the decline 10 
in unmodified cells, suggesting engrafting of the cells and resistance to HIV infection [75]. 11 
The aforementioned CRISPRa system can also be exploited to influence the expression of key cellular host 12 
factors representing anti-viral defense in human cells, such as antiviral restriction factors. This approach was 13 
applied in an HIV-1 model of infection of human CD4+ T cells to enhance the expression of the antiviral genes 14 
APOBEC3G and APOBEC3B, members of the cytidine deaminase gene family that can edit newly synthetized 15 
HIV provirus intermediates. As APOBEC3G is susceptible to degradation by the HIV-1 Vif protein, whereas 16 
APOBEC3B is resistant, only the induced APOBEC3B inhibited wild-type HIV-1 infectivity whereas 17 
APOBEC3G inhibited replication of a Vif-deficient (ΔVif) HIV-1 provirus [76]. Such strategy could also be 18 
applied to other viruses such as HBV, in which stimulation of IFN by APOBEC3A and 3B [77] or Toll-like 19 
receptor 7 [78] has been reported to induce degradation of HBV cccDNA. 20 
From a virological perspective, targeting host factors required for viral infection and replication with 21 
programmable nucleases will open up a number of possibilities for basic research. Genome-scale CRISPR–22 
Cas9 screens are already employed to globally investigate the effects of individual human gene products on 23 
the biological cycle of clinically relevant viruses, including HCV, HIV, dengue virus, Zika virus, and West 24 
Nile virus, leading to new insights into viral molecular biology and giving the opportunity to provide new 25 
potential targets for antiviral drug development [79].  26 
 27 
4. Bacterial infections 28 
The CRISPR–Cas9 system has evolved in bacteria and archea as an acquired immune system to protect against 29 
invading phages and plasmids. These systems can be repurposed for lethal self-targeting, leading to selective 30 
bacterial elimination. Due to the lack of efficient DNA repair pathways, bacteria are particularly susceptible 31 
to genomic DNA damage and cell death as compared to eukaryotic cells. Furthermore, nuclease-deactivated 32 
Cas9 can be used to control bacterial gene expression, rather than to cleave DNA sequences [80]. Genome 33 
editing-based antimicrobial strategies are illustrated in Figure 2.   34 
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4.1. Lethal self-targeting of bacterial genomes 1 
As mentioned above, an obvious application of CRISPR–Cas systems is their repurposing for self-targeting 2 
and damaging bacterial genomes, leading to cell death [81-83]. The proof-of-principle of this approach was 3 
demonstrated in the Escherichia coli model by engineering potent type I CRISPR–Cas systems, which cleave 4 
and degrade DNA through the action of the 3’-to-5’ exonuclease Cas3 [84]. In this model, genome targeting 5 
was highly sequence-specific and allowed the selective elimination of targeted bacterial strains within mixed 6 
cultures. Cell killing was the result of chromosomal injury, since it was similarly potent regardless of the 7 
targeted locus, its genomic location, and transcriptional activity. Similar results were achieved by engineering 8 
type II CRISPR–Cas systems, in which the Cas9 endonuclease causes double-strand cleavage of target DNA 9 
sequences [85,86]. The type I CRISPR–Cas system is expected to be more efficient in inducing DNA damage 10 
and cell killing than type II systems, because its exonuclease activity results in large-scale genomic alterations 11 
[86,87], thus enabling more potent eradication of a bacterial population. In addition, the type I CRISPR–Cas 12 
systems is widespread in many pathogenic bacteria, such as E. coli or Clostridium difficile [88], and could be 13 
repurposed to their self-targeting.  14 
Treatment with CRISPR-Cas-based antimicrobials may lead to uncomplete killing of bacteria populations, 15 
mainly due to inefficient delivery of the CRISPR-Cas system and to the emergence of defective CRISPR-Cas 16 
[84,85,89]. However, when applied to a mixed bacterial population, sequence-specific antimicrobials allow 17 
non-targeted cells to keep growing, which may in turn compete with the small proportion of targeted cells that 18 
survive the treatment. 19 
4.2. Targeting bacterial antibiotic resistance and virulence genes.  20 
Antibiotic-resistance and virulence genes represent elective targets for sequence-based antimicrobial 21 
strategies. These genes often reside in mobile elements, such as conjugative plasmids, phages, and transposons, 22 
and may be horizontally transferred and disseminated. Targeting antibiotic-resistance and virulence genes is 23 
feasible because the number of relevant pathogens responsible for the majority of antibiotic-resistant infections 24 
in humans is relatively small (e.g., Klebsiella pneumoniae, Staphylococcus aureus, Enterococcus faecium, 25 
Acinetobacter baumannii, and Pseudomonas aeruginosa), thus requiring the development of only a limited 26 
number of tools. Actually, the emergence and worldwide spread of these multidrug-resistant bacteria is a 27 
serious threat to public health, leading to significant morbidity, mortality, and increase of healthcare costs.  28 
Targeting bacterial antibiotic resistance and virulence genes was pursued by Citorik et al. [85] and Bikard et 29 
al. [89], who also addressed the difficult task of developing efficient methods to deliver genome editing tools 30 
into target bacterial cells. Citorik et al. [85] exploited two different horizontal genetic transfer systems of 31 
bacteria to deliver molecular constructs to bacterial cells, i.e. plasmid conjugation and viral transduction. The 32 
first approach, based on a broad-host-range conjugative plasmid carried by an E. coli strain, was hampered by 33 
low conjugation efficiency. The second delivery system was based on a M13-phagemid vector, i.e., a plasmid 34 
encoding specific genes packaged into a phage capsid. Phagemids were engineered to carry CRISPR-Cas9-35 
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based RNA-guided nucleases targeting the blaSHV-18 or blaNDM-1 genes, which confer extended-spectrum and 1 
pan-resistance to β-lactam antibiotics, respectively. Treatment with phagemids of E. coli strains carrying the 2 
resistance genes resulted in a significant reduction of viable cells, while no toxicity was observed in wild-type 3 
E. coli strains. Interestingly, the mechanisms of cell killing after targeted cleavage of endogenous plasmids 4 
were shown to result from the activation of plasmid-borne toxin-antitoxin systems. The specificity of the 5 
CRISPR-Cas system was challenged by targeting a single-nucleotide mutation in the chromosomal DNA 6 
gyrase gene (gyrAD87G), which confers resistance to quinolone antibiotics. Experiments showed that a targeted 7 
phagemid vector selectively killed only E. coli cells harboring the gyrAD87G mutation, but not other E. coli 8 
strains with the wild-type gyrA gene [85]. To demonstrate the versatility of the CRISPR-Cas system to combat 9 
pathogens, this was engineered to target the chromosomal eae gene, which encodes intimin, a cell-surface 10 
adhesin in enterohemorrhagic E. coli O157:H7 (EHEC) that is necessary for intestinal colonization and tissue 11 
damage. However, eae targeting led to only a 20-fold reduction of EHEC cell viability, probably because of 12 
inefficient phagemid delivery to this bacterial strain. Anyway, treatment significantly increased the survival of 13 
EHEC-infected G. mellonella larvae, an in vivo infection model to assess the efficacy of antimicrobials [85].  14 
Bikard et al. [89] used a similar CRISPR-Cas9-based approach to target antibiotic resistance and virulence 15 
genes in bacteria, but exploited the ΦNM1 phage for phagemid encapsidation and S. aureus as the model 16 
pathogen. A CRISPR-Cas9 antimicrobial that targeted the methicillin resistance gene mecA led to a marked 17 
decrease of mecA-carrying S. aureus in mixed cultures, while CRISPR-Cas9 that targeted a plasmid conferring 18 
tetracycline resistance in S. aureus did not result in cell death, but in selective degradation and loss of the 19 
plasmid in a bacterial population. In addition, this CRISPR-Cas9 antimicrobial could immunize nonpathogenic 20 
S. aureus strains against the transfer of antibiotic-resistant plasmids. In vivo tests in a mouse model of skin 21 
colonization showed that CRISPR-Cas9 phagemids selectively reduced the proportion targeted S. aureus 22 
strains, more efficiently than standard treatment with the topical antibiotic mupirocin [89].  23 
An improvement to CRISPR-Cas9 antimicrobial strategies was achieved by combining spacers targeting 24 
antibiotic resistance with spacers conferring a selective advantage to antibiotic-sensitive bacteria by protection 25 
from a lytic phage [90]. The engineered CRISPR-Cas system was introduced into a λ prophage, and thus made 26 
transferable to bacteria by lysogenization. When treated with lytic phages, lysogenized bacterial were 27 
protected, enabling the positive selection of a population of antibiotic-sensitized bacteria [90].   28 
4.3. Driving bacterial gene expression  29 
Nuclease-deactivated Cas9, termed dCas9, in which the RuvC and HNH nickase domains have been mutated, 30 
is unable to cleave DNA but retains its ability to bind specific DNA sequences when guided by a sgRNA 31 
[80,91,92]. Regulation of gene expression by dCas9 was first demonstrated in E. coli, where delivery of dCas9 32 
with a sequence-specific sgRNA led to inhibition of gene expression (CRISPR interference, CRISPRi) [93]. 33 
The dCas9-sgRNA complex interferes with gene expression probably by blocking RNA polymerase or by 34 
hindering the binding of transcription activators [93]. Like the CRISPR-Cas9 nuclease, CRISPRi is highly 35 
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efficient, has minimal off-target effects, and is multiplexable, allowing the simultaneous repression of multiple 1 
genes. However, in bacteria, CRISPRi is polar, since any operon gene downstream or upstream of the dCas9 2 
binding site is silenced in addition to the targeted gene [94,95]. As mentioned above, mutant dCas9 can be also 3 
used as a fusion protein to activate gene expression (CRISPRa). For example, dCas9 fused with the ω-subunit 4 
of E. coli RNA polymerase enhanced gene expression by facilitating assembly of the enzyme to the targeted 5 
promoter [96]. Applications of the CRISPRi and CRISPRa technology to regulate gene expression in bacteria 6 
are still limited [93, 95-98]. In Mycobacterium tuberculosis, CRISPRi mediated by dCas9 from Streptococcus 7 
thermophilus could efficiently and specifically knockdown gene expression and inhibit cell growth after 8 
targeting essential genes [94]. In addition, CRISPRi proved its usefulness in dissecting the mycobacterial folate 9 
biosynthesis pathway, with potential utility in drug target discovery [94].  10 
 11 
5. Fungal infections 12 
Antimicrobial strategies based on targeting drug-resistance and virulence genes, which have been developed 13 
against bacteria, could potentially be applied to eukaryotic pathogens, such as yeast, protozoa, and nematodes. 14 
However, these organisms have a larger size and diploid genome and more efficient DNA repair mechanisms 15 
than prokaryotes, making them less susceptible to the lethal effects of gene targeting. At variance, their genome 16 
may be easily modified by genome editing technologies, which are providing powerful research tools to dissect 17 
the basic mechanisms of infection and pathogenesis. Despite these advances, efficient intracellular delivery of 18 
exogenous biomolecules remains a major challenge for genome editing applications. 19 
The CRISPR/Cas9 system has been optimized and adapted to fungi by using fungal constitutive or inducible 20 
promoters to drive Cas9 and sgRNA expression and codon-optimized Cas9 [99-104]. In addition, methods to 21 
achieve transient expression of Cas9 have been developed, in order to limit its cytotoxic effects [103]. The 22 
CRISPR-Cas9 complex has been delivered to fungi through transformation mediated by polyethylene glycol, 23 
agrobacterium, and blastospores [102]. CRISPR-Cas9 has been successfully applied in the genetic 24 
manipulation of several fungi, including model organisms, such as Schizosaccharomyces pombe [105] and 25 
Saccharomyces cerevisiae [106-108], and fungal pathogens, such as Aspergillus fumigatus [99,109], Candida 26 
albicans [110,111], other Candida species [112-114], and Cryptococcus neoformans [115,116], paving the 27 
way for applications in pathogenesis studies, characterization of mechanisms of drug resistance, and drug 28 
discovery.  29 
 30 
6. Parasite infections  31 
Studies that used genome editing technologies to target the genome of protozoa and nematodes aimed mainly 32 
at developing easy and efficient methods for gene knock out and genome engineering, with applications in 33 
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reverse genomics for the identification of virulence genes, new drug targets, and drug resistance mechanisms, 1 
while direct genome targeting has not been exploited so far for therapeutic purposes.  2 
For example, ZFNs have been used to generate deletions, allelic replacement, and specific point mutations in 3 
endogenous genes of Plasmodium falciparum, including point mutations in the chloroquine resistance 4 
transporter gene [117]. CRISPR-Cas9 has been used to rapidly generate specific gene knockouts and single-5 
nucleotide substitutions in P. falciparum [118-121], leading to the characterization of mutations associated 6 
with drug-resistance. Gene editing strategies to attenuate or kill malaria parasites for vaccine development and 7 
therapy have been proposed [122]. CRISPR-Cas9 allowed characterizing drug-resistance mutations and new 8 
potential therapeutic targets in Toxoplasma gondii [123-125]. In Trypanosoma cruzi, knock down of multiple 9 
genes was performed for functional genomics studies [126,127]. Proof of concept of CRISPR-Cas9-mediated 10 
genome editing was demonstrated for Leishmania major [128] and Leishmania donovani [129], with the 11 
introduction of loss-of-function insertion and deletion mutations.  12 
The CRISPR-Cas9 technology has been also applied to the model organism Caenorhabditis elegans [130,131], 13 
a nematode that is widely used for the study of metazoan biology and for parasitology research. In multicellular 14 
parasite organisms, efficient in vivo delivery of genome editing constructs is even a more critical issue, in order 15 
to allow biallelic targeting of multiple cells in different tissues. Enrichment of genome editing events, which 16 
has been achieved in arthropods by using gene drivers [132] and mutagenic chain reaction [133], could be 17 
potentially applied to expand modified genetic traits in parasite populations.    18 
 19 
7. Vector-borne infections  20 
Vector-borne infectious diseases, which include infections caused by viruses, bacteria, and parasites, represent 21 
a relevant burden of disability and death, especially in developing countries. The most effective strategies to 22 
combat vector-borne infectious diseases are based on the control of arthropod vectors, which is hindered by 23 
increasing insecticide resistance. Novel approaches to control vector populations, especially mosquitoes, used 24 
genetic engineering technologies to generate genetically modified and sterile strains [134,135]. In particular, 25 
gene drive systems are exploited to rapidly spread these genetic modifications throughout vector populations, 26 
in order to promote their crash or to propagate alleles that make vectors less competent to pathogen 27 
transmission. Gene drives are selfish genetic elements that are transmitted to progeny more frequently than 28 
expected from Mendelian genetics. Example of gene drive systems found in nature are represented by 29 
transposable elements and homing endonuclease genes, and they have been already applied to generate 30 
transgenic mosquitoes [135,136]. The advent of CRISPR-Cas9 tools has allowed overcoming technical hurdles 31 
and to speed up the development of artificial gene drives, with relevant results already achieved [134-136], 32 
such as the introduction of anti-P. falciparum effector genes [137] and the inactivation of female fertility genes 33 
[132] in Anopheles mosquitoes to combat malaria. The risks related to potential off-target effects, the 34 
emergence of resistant strains of vectors, the ecological impact of suppression of mosquitoes and other vector 35 
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populations, and the spread in the environment of genetically modified organisms should be carefully evaluated 1 
before field implementation of these new technologies in vector control programs [135,138].   2 
 3 
8. Expert commentary 4 
8.1. Safety concerns 5 
An important feature to keep in mind when designing a strategy with programmable nucleases is the risk of 6 
off-target effects, namely the possibility that other undesired loci of the human genome, homologous to the 7 
one to target, might be cleaved, giving rise to perturbations in the DNA that can lead to disease or tumor 8 
formation. Notwithstanding, in the human genome the recognition of a DNA sequences of 17 or more bp  9 
should minimize this event [139], actually, all the above mentioned nucleases can cause off-target mutations 10 
[20, 140-142]. The off-target activity of ZFNs, TALENs and CRISPR-Cas9 depends exclusively on the 11 
specificity of their DNA-binding domains, as their cleavage domain is not DNA-specific. ZFN-induced off-12 
target effects are likely determined by the complex context dependence of the ability of ZF domains to bind 13 
DNA as well as the frequency and location of sites in the genome actually bound by ZFNs [141,143], thus 14 
being highly dependent on the ZFN being tested. As TALE domains are less tolerant of target sequence 15 
mismatches than ZFs, TALENs are likely to have higher specificity for target-binding site and cleavage [144]. 16 
Although several studies have shown that the CRISPR-Cas9 system can exert off-target activity in vitro, recent 17 
in vivo studies showed how this system is highly specific and rarely exert off-target effects [145,146]. In 18 
contrast, whole genome sequencing analysis indicated that sgRNAs might exert mutations in vivo in noncoding 19 
RNAs or other regulatory intragenic regions that are independent of the target loci and that could be harmful 20 
to key cellular processes [147]. The results raise important safety issue for clinical applications of CRISPR-21 
Cas9, but need to be further investigated and confirmed. There are several strategies that can be applied in 22 
order to reduce the off-target effect of programmable nucleases. HEs usually show very high specificity for 23 
their DNA targets and exert less off-target cleavage, as demonstrated by low toxicity in vitro, even if expressed 24 
at high levels [23].  25 
Significant reduction of off-target cleavage has been achieved by choosing unique target sites without highly 26 
homologous sequences within the human genome [148,149]. A further reduction was accomplished by 27 
approaches focused on the cleavage domain such as forcing FokI subunits to interact as obligate heterodimers 28 
[150], by replacing it with a DNA-specific nuclease (such as HE) [151] or by using chimeric enzymes [149]. 29 
For example, HPV18 was successfully targeted by fusing the staphylococcal nuclease, cleaving DNA as a 30 
monomer, to a ZF protein thus not requiring dimerization [55]. Moreover, the avoidance of unwanted indels 31 
was achieved by converting FokI or Cas9 into nickases exerting SSBs [148,153,154]. Such system proved to 32 
be successful in targeting HBV by designing two pairs of guides to introduce a DSB at target DNA with no 33 
apparent off-target mutations detected [155,156]. Furthermore, the use of truncated sgRNAs [157] or larger 34 
PAM sequences, demonstrated reduction of off-target cleavage with efficient on-target editing [158]. Finally, 35 
14 
 
the delivery of nucleases in form of mRNAs or proteins can lead to faster expression and lower toxicity 1 
compared to plasmids due to the rapid degradation into the host cells [159,160]. Despite the optimistic low 2 
rate of off-target events reported for all classes of nucleases, post editing verification such as next generation 3 
sequencing methods will be necessary in order to add confidence to results by increasing numbers and quality 4 
of reads of off- target sites. 5 
Since all the four classes of nucleases originate in part from non-human organisms, they are potential 6 
immunogens that can redirect the immune-responses and trigger the clearance of the transfected cell. To date, 7 
few data are available on the in vivo toxicity or immunogenicity of programmable nucleases. Clinical trials 8 
with ZFNs showed no toxicity or immunogenicity, but the delivery of ZFNs to CD4+ T cells was done ex vivo, 9 
allowing for expansion of corrected cells before transplantation into patients [75]. In therapeutic mouse models 10 
of HBV and HPV infection, no in vivo toxicity was observed with TALENs [64,161].  11 
Other important safety problems are represented by either the potential occurrence of multiple DNA DSBs in 12 
the same genome that might lead to genomic rearrangements or by the risk that cleavage of episomal genomes 13 
of viruses, such as HBV and HPV, with subsequent linearization, could promote their random integration into 14 
the target cells and hence the risk of tumor development. As the long-term effects of exposure to programmable 15 
nucleases in vivo remains unknown, safety procedures such as the use of tissue-specific, drug-inducible, or 16 
non-constitutive viral promoters, together with evaluation of the possible off-target effects and multiplexed 17 
targeting within the virus genome, should be taken into consideration to ensure the safety of the procedure. 18 
8.2. Delivery challenges 19 
When designing a therapeutic strategy with programmable nucleases, the delivery method is one of the most 20 
important hurdles to face. In fact, to obtain a therapeutic effect, nucleases must be delivered efficiently to 21 
infected cells and expressed at high levels. Several factors must be taken into consideration: the type of 22 
pathogen, the type of infected cell that need to be targeted, the accessibility of the anatomical site of infection, 23 
the dosing necessary to exert the desired effect, and the type of delivery system. Pathogens that are primarily 24 
found in a restricted anatomic site will be more suitable for the targeted delivery of programmable nucleases, 25 
whereas pathogens capable to infect blood cells or multi organs may be more challenging to treat in vivo, since 26 
they require systemic delivery. Ex vivo delivery is considered safer than in vivo delivery, but it has been applied 27 
so far only to treat disorders of the hematopoietic system. Several delivery approaches, based on virus-free 28 
system (such as electroporation, liposomes) and viral vectors (such as lentiviral vectors, adenoviral vectors, 29 
AAV vectors, phagemid vectors), have been developed and applied in clinical trials for delivery of therapeutic 30 
genes [162]. Methods based on non-viral delivery systems are less immunogenic and have a lower risk of 31 
chromosomal integration than viral vector-based approaches, but transfection efficiency is usually lower and 32 
not cell-type specific. For example, the liver is a good target for infection by AAV vectors, especially AAV8, 33 
which can be used to transduce HBV-infected hepatocyte in vivo. Viral vector have limitations in their capacity 34 
to accommodate foreign sequences, including those encoding programmable nucleases. Specifically, HEs are 35 
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the smallest class of programmable nucleases (about 250 amino acids) and this facilitates their insertion into 1 
any delivery vector. ZFNs, in turn, are smaller than TALENs and, unlike the latter, can be incorporated into 2 
small-capacity AAV vectors [46] or integrase deficient lentiviral vectors [163]. In addition, the highly repetitive 3 
nature of the coding sequences for ZFNs and TALENs represent a challenges in viral packaging, due to 4 
undesired recombination during the production process [164]. Since the enzyme Cas9 has a large size, smaller 5 
Cas molecules that can be efficiently packaged into small capacity viral vectors have been engineered, such as 6 
Cas from S. aureus [165-167].  7 
Phages are ideal vectors for gene transfer in bacterial cells, since they have evolved to infect and introduce 8 
their genetic material into bacteria. However, their potential clinical use in humans is limited to the treatment 9 
of bacterial infections in external sites, such as external ear infections or burn wound-associated infections. In 10 
fact, after systemic injection in mice, most phages are rapidly sequestered by the liver and the spleen [168]; in 11 
addition, the narrow host range of phages limits their application to different pathogens, while the relatively 12 
large size hinders efficient diffusion into infected tissues; finally, induction of neutralizing antibodies prevents 13 
the possibility of repeated administrations of phages [169].    14 
The use of non-viral delivery methods for bacterial cells is hampered by the cell wall. A recent study [170] 15 
developed a novel non-viral delivery method, called Cr-Nanocomplex, which was based on a nanocomplex of 16 
polymer-derivatized Cas9 protein and sgRNA targeting bacterial antibiotic resistance. In particular, in the 17 
nanocomplex, recombinant Cas9 was covalently modified with branched polyethylenimine, a cationic 18 
polymer, as the carrier for packaging sgRNA. At variance with approaches used for mammalian cells, based 19 
on the noncovalent encapsulation of Cas protein and sgRNA into nanoparticles and characterized by low 20 
loading and packaging efficiencies, the direct covalent modification of the protein allowed to minimize the 21 
amount of carrier material and hence its toxicity. In vitro experiments showed that a Cr-Nanocomplex targeting 22 
mecA could be successfully delivered into methicillin-resistant S. aureus, resulting in reduced growth of 23 
bacteria [170]. 24 
8.3. Emergence of resistant pathogens  25 
Another concern about the use of programmable nucleases for the treatment of infectious diseases is the 26 
emergence of escape mutants that develop resistance to treatment. These mutants could be the result of the 27 
acquisition of genetic changes in target sites acquired during replication or may be induced by the nucleases 28 
themselves. This scenario is more likely to occur in error-prone RNA viruses than DNA viruses [171]. The 29 
emergence of endonuclease resistance can be prevented by multiple targeting of different regions of pathogen 30 
genome [175]. Replication-competent HIV-1 with mutation in nuclease target sites emerged after exposure to 31 
ZFNs targeting reverse transcriptase [172] or to CRISPR-Cas9 targeting HIV proviral DNA [173].  32 
Anti-bacterial and anti-parasitic therapies based on programmable nucleases may also induce the emergence 33 
of escape mutants, characterized for example by a defective CRISPR-Cas, with loss of spacer sequences or 34 
deletion of the cas9 gene [84,85,89]. Importantly, the occurrence of escape mutations in the targeted sequence 35 
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was not observed in experimental studies, indicating a low risk for the emergence of resistant bacterial strains 1 
[89].  2 
 3 
9. Five-year view 4 
Despite the great advances that have been made in the past few years with proof-of-concept studies 5 
demonstrating the feasibility of harnessing programmable nucleases for the treatment of antimicrobial 6 
diseases, many more are needed to concretely translate them into clinical and field applications. Obstacles that 7 
still should be overcome are mainly related to the safety issue. Thus, in a five-year view, advances are expected 8 
in the generation of nucleases lacking off-target effects and with higher cleavage efficiency, and in the 9 
development of sensitive diagnostic methods to detect the presence of off-target mutations. The applicability 10 
of genome editing-based antiviral therapy has been proven in clinical trials of ZFN-based inactivation of the 11 
CCR5 gene to block HIV-1 infection [75], but further clinical studies are warranted in the next years to test 12 
safety and effectiveness of genome editing-based therapies. Another problem to be solved is the improvement 13 
in the efficiency and safety of delivery systems for programmable nucleases, especially if directing them for 14 
in vivo administration is the goal. Viral vectors have been widely used for genome editing in the research field, 15 
but it is expected that non-viral vectors will have more chances to be approved for clinical applications. Topical 16 
treatment of infections involving external sites, such as skin, mucosa, burn wounds and the eye, will probably 17 
have more chances of success than treatment of systemic infections. Development of strategies based on fine 18 
dosing and transient intracellular expression of the gene editing machinery is also preferable, since continuous 19 
expression of high-levels nucleases in the long run may increase the risk of off-target effects and the emergence 20 
of escape mutants. Definitely, before moving to the bedside, studies in suitable in vivo animal models will be 21 
necessary, but with the important limitation that animal models are not available for all infectious diseases.  22 
 23 
Key issues 24 
 Programmable nucleases, such as ZFNs, TALENs, CRISPR-Cas9 and HEs, are molecular scissors that 25 
can be targeted at predetermined loci in order to modify the genome sequence of an organism. The 26 
main mechanisms by which programmable nucleases can be employed for the treatment of infectious 27 
diseases is the introduction of mutations into the genome by the error-prone NHEJ mechanism.  28 
 Programmable nucleases can be exploited as antiviral treatment by targeting essential viral genes or 29 
host factors that are required for viral infection and replication. Efficiency of these strategies has 30 
already been proven in vitro and in vivo models of HIV, HBV, HSV, and HPV infection. Phase I 31 
clinical trials have been initiated to tests safety and efficacy of targeted nucleases in patients with HIV 32 
infection and with HPV-related cervical lesions.   33 
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 As bacteria are particularly susceptible to genomic DNA damage and cell death compared to 1 
eukaryotic cells, the CRISPR-Cas9 systems has been redirected for lethal self-targeting, allowing 2 
selective elimination of targeted bacterial strains. In addition, CRISPR-Cas9 has been employed to 3 
target antibiotic-resistance genes and virulence genes. Furthermore, nuclease-deactivated Cas9 has 4 
been used to interfere with bacterial gene expression by blocking RNA polymerase or by hindering 5 
the binding of transcription activators. 6 
 Feasibility of using programmable nucleases to modify the genome of parasites and fungi and to 7 
manipulate the genome of arthropod vectors has been demonstrated, opening perspective for 8 
therapeutic and vector-control applications. 9 
 In the past few years, many progresses have been made in demonstrating the feasibility of 10 
programmable nucleases as therapeutic strategy for the treatment of infectious diseases. However, 11 
there are still many hurdles to overcome such as the safety issues, mostly dictated by the risk of off-12 
target mutations, the raising of escape mutants, and the inefficiency of delivery methods, before 13 
translating results from preclinical studies into clinical and field applications. 14 
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 1 
Figure legends 2 
Figure 1. Genome editing strategies for antiviral therapy. Targeting viral genome: programmable 3 
nucleases can be exploited for the direct targeting of virus genome leading to disruption of essential viral genes. 4 
Targeting of integrated viral genome: integrated viruses such as HIV can be targeted at both LTRs leading 5 
the excision of the provirus. Alternatively, programmable nucleases can act throughout NHEJ to disrupt 6 
essential viral sequences. Targeting key host factors: programmable nucleases can target viruses key host 7 
factors essential for virus entry/replication. Activating viruses/restriction factors: nucleases activation can 8 
be directed to induce virus reactivation in latently infected cells, triggering the immune system to recognize 9 
infected cells; the same system can be applied to activate host restriction factors that can block the virus at 10 
different biological levels. 11 
 12 
Figure 2: CRISPR-based strategy as antimicrobials. Lethal self-targeting of bacterial genomes: by 13 
delivering, via engineered phages, self-targeting spacers, endogenous Cas3 exonuclease can be redirected, 14 
leading to chromosome targeting and degradation. Targeting bacterial antibiotic resistance genes: 15 
chromosome targeting and degradation can be achieved also by gRNA/Cas9 system to generate DNA DSBs, 16 
which can be edited using the endogenous DNA repair pathways. Alternatively the same approach can be 17 
adopted by using nanosized CRISPR complexes (Cr-Nanocomplex), polymer-derivatized Cas9 complexed 18 
with sgRNA targeting antibiotic resistance. Blocking virulence gene transcription: The block of 19 
transcription can be obtained by using a deactivated Cas9 (dCas9), able to bind but not cleave the target 20 
sequence. 21 
 22 
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